mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, has appointed Jurgen Van Broeck as Chief Executive Officer.
Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area
Mundipharma and Vectura announce plans to reformulate flutiform® (fluticasone propionate/formoterol fumarate) pressurised metered-dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint
CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma today announced rezafungin (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults.
CAMBRIDGE, England--(BUSINESS WIRE)--For Trade and Medical Media Only: Mundipharma today announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for rezafungin for the treatment of invasive candidiasis in adult patients. The MAA is based on results from the pivotal ReSTORE Phase III clinical trial, which demonstrated statistical non-inferiority of rezafungin dosed once weekly when compared to the current standard of care, caspofungin, dosed once daily. This trial provides evidence of efficacy and safety of rezafungin as potential first-line treatment for candidemia and invasive candidiasis.
Mundipharma and Cidara Therapeutics have presented data from the Phase III ReSTORE trial of rezafungin, in the treatment of candidemia and/or invasive candidiasis.
SAN DIEGO & CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today presented data from the Phase 3 ReSTORE clinical trial of rezafungin in the treatment of candidemia and/or invasive candidiasis at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The data, presented in a late-breaking poster, showed non-inferiority for rezafungin dosed once-weekly compared to caspofungin, the current standard of care, dosed once-daily, for both primary endpoints.1
SAN DIEGO and CAMBRIDGE, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced that the companies will present new clinical data...
SAN DIEGO & CAMBRIDGE, England--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis.